Circulatory endostatin level and risk of cardiovascular events in patients with end-stage renal disease on...

Area of Science:

• Nephrology
• Cardiology
• Biomarker Research

Background:

• Endostatin, involved in extracellular matrix remodeling, plays a role in vascular pathology and cardiovascular disease.
• Its utility as a biomarker for vascular calcification and cardiovascular events in hemodialysis patients is not well-established.

Purpose of the Study:

• To investigate the association between circulating endostatin levels and vascular calcification, mineral bone disease biomarkers, and cardiovascular events in hemodialysis patients.
• To determine if endostatin can serve as a predictive biomarker for cardiovascular events in this population.

Main Methods:

• Prospective recruitment of 372 hemodialysis patients.
• Baseline plasma endostatin levels measured and analyzed for associations with mineral bone disease biomarkers and abdominal aortic vascular calcification.
• Primary endpoint: composite of cardiovascular and cardiac events.

Main Results:

• Higher endostatin levels correlated with LDL cholesterol and systolic blood pressure but not with mineral bone disease markers or vascular calcification.
• Patients in the highest endostatin tertile showed significantly higher cumulative rates of composite cardiovascular and cardiac events.
• Multivariate analysis revealed endostatin tertile 3 was associated with a 4.37-fold increased risk for composite cardiovascular events and 3.88-fold for cardiac events.

Conclusions:

• Elevated circulating endostatin levels are independently associated with atherosclerotic risk factors in hemodialysis patients.
• Endostatin levels did not correlate with mineral bone disease markers or vascular calcification.
• Higher endostatin levels are a significant independent predictor of increased risk for cardiovascular events in hemodialysis patients, identifying them as a valuable biomarker.